Through multiple mechanisms explained below, SFN prevented cognitive impairment in experimental models of AD by reducing biomarkers of Aβ, tau, inflammation, oxidative stress, and neurodegeneration [240]. The gene discussed is MAPT; the disease is Alzheimer disease.